Matinas BioPharma Holdings (MTNB) Net Income towards Common Stockholders (2014 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Net Income towards Common Stockholders of -$1.9 million for Q1 2026, down 16.0% year-over-year from -$2.3 million in Q1 2025, and up 63.37% quarter-over-quarter from -$5.2 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Net Income towards Common Stockholders for 13 consecutive years, with -$1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 16.0% year-over-year to -$1.9 million; the TTM figure through Mar 2026 stood at -$11.4 million (up 52.56% YoY), while the FY2025 annual figure was -$11.0 million, up 54.79% from the prior year.
- Net Income towards Common Stockholders rose to -$1.9 million in Q1 2026 per MTNB's latest filing, from -$5.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$1.7 million in Q1 2025 and bottomed at -$9.7 million in Q2 2024.
- Historically, Net Income towards Common Stockholders has averaged -$5.3 million across 5 years, with a median of -$5.9 million in 2023.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders slumped 62.0% — and 2025, when it soared 78.29%.
- Matinas BioPharma Holdings' Net Income towards Common Stockholders stood at -$3.6 million in 2022, then plunged by 62.0% to -$5.9 million in 2023, then sank by 43.22% to -$8.4 million in 2024, then jumped by 37.8% to -$5.2 million in 2025, then surged by 63.37% to -$1.9 million in 2026.
- Business Quant data shows MTNB's Net Income towards Common Stockholders at -$1.9 million in Q1 2026, -$5.2 million in Q4 2025, and -$2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | -1.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.33 Mn |
| Mar 31, 2026 | -1.92 Mn |
| Dec 31, 2025 | -5.25 Mn |
| Sep 30, 2025 | -2.15 Mn |
| Jun 30, 2025 | -2.11 Mn |
| Mar 31, 2025 | -1.66 Mn |
| Dec 31, 2024 | -8.43 Mn |
| Sep 30, 2024 | -4.28 Mn |
| Jun 30, 2024 | -9.72 Mn |
| Mar 31, 2024 | -6.85 Mn |
| Dec 31, 2023 | -5.89 Mn |
| Sep 30, 2023 | -7.17 Mn |
| Jun 30, 2023 | -7.20 Mn |
| Mar 31, 2023 | -6.66 Mn |
| Dec 31, 2022 | -3.63 Mn |
| Sep 30, 2022 | -5.46 Mn |
| Jun 30, 2022 | -5.92 Mn |
| Mar 31, 2022 | -5.98 Mn |
| Dec 31, 2021 | -6.70 Mn |
| Sep 30, 2021 | -6.84 Mn |